^
    2ms
    A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov)
    P1, N=60, Recruiting, Dren Bio | Not yet recruiting --> Recruiting
    Enrollment open
    |
    DR-01
    2ms
    A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Dren Bio
    New P1 trial
    |
    DR-01
    2years
    DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia (ASH 2022)
    In addition, treatments are limited to standard immunosuppressive therapy such as methotrexate, cyclosporine or cyclophosphamide, with complete response rates of only 50% or less for each agent. Additional profiling and evaluation of DR-01 in LGLL patient samples ex vivo as part of a pre-phase I study is ongoing. A phase I/II trial has been initiated to assess the safety and efficacy of DR-01 in previously treated LGLL patients.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LAMP1 (Lysosomal Associated Membrane Protein 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    cyclophosphamide • methotrexate • cyclosporine • DR-01